^
    almost4years
    Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (PubMed, Clin Lymphoma Myeloma Leuk)
    PNT2258 was well-tolerated in a chemotherapy refractory DLBCL population. Despite demonstration of single-agent activity, ORR was lower than acceptable for further new therapy development.
    Clinical • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    rosomidnar liposomal (PNT2258)
    almost4years
    A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies. (PubMed, Clin Lymphoma Myeloma Leuk)
    Clinically meaningful and durable activity with an acceptable safety profile was observed in participants with relapsed/refractory B-cell malignancies who received single-agent PNT2258.
    P2 data • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    rosomidnar liposomal (PNT2258)